Name of this trial: Majestic-7
What type of cancer is this for? Multiple Myeloma
Who is this trial for? This trial is for patients with newly diagnosed multiple myeloma who are either ineligible or not intended for stem cell transplant as initial therapy.
What biomarkers are involved? n/a
What is the National Clinical Trial #? NCT05552222
Brief summary of this trial: This is a phase 3 randomized trial, comparing Teclistamab in combination with Daratumumab injection and lenalidomide (oral) VS. Talquetamab in combination with Daratumumab injection and lenalidomide (oral), No placebo in this trial, all patients will receive treatment.
Need to know: Teclistamab and Talquetamab are both injection medications, not IV. Both drugs recently approved to be given in outpatient setting and no longer requiring hospitalization for monitoring. Home monitoring of vital signs and required family member presence/driving after first 3 doses to ensure patient safety. First 3-4 weeks of treatment has a busy schedule, however after first cycle visits are more spaced out.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]
Name of this trial: EXCALIBER-Maintenance
What type of cancer is this for? Newly diagnosed Multiple Myeloma (NDMM)
Who is this trial for? 1) Patients who have received 3 to 6 cycles of an induction therapy. Post-stem cell transplant consolidation is permitted. 2) Patients within 12 months from initiation of induction who achieved at least a partial response after Autologous Stem Cell Transplantation, with or without consolidation.
What biomarkers are involved? None
What is the National Clinical Trial #? NCT05827016
Brief summary of this trial: The study is comparing Iberdomide maintenance vs. Lenalidomide maintenance therapy after Autologous Stem Cell Transplantation (ASCT) in patients with newly diagnosed multiple myeloma.
Need to know: Patients will be randomized 50:50 to either Iberdomide or Lenalidomide. Both medications are oral drugs, Iberdomide is taken 21 days out of a 28-day cycle, and Lenalidomide is taken 28 days out of a 28-day cycle. Treatment continues until progression of disease or until medications are not tolerated by patient.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]